Latest Intellia Therapeutics News & Updates

See the latest news and media coverage for Intellia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Intellia Therapeutics (Intellia)

Clinical-stage genome editing company

intelliatx.com
Headquarters
Cambridge, United States
Founded year
2014
Company type
Public company
Number of employees
450–500

Last updated

Latest news about Intellia Therapeutics (Intellia)

In short: Intellia reported positive Phase 3 results for its CRISPR therapy lonvo-z and initiated a rolling BLA submission following mixed clinical outcomes.

Company announcements

Intellia

Intellia announces proposed public offering of $150 million common stock

The offering includes an underwriters' option for additional shares, with Jefferies, Goldman Sachs, and Citigroup as joint book-runners.

Unlock all announcements with a

Media coverage

Investor's Business Daily

Why This Gene-Editing Stock Is Soaring

Intellia stock surged Monday on promising results for the biotech company's gene-editing approach to a swelling disorder.

Taiwan News

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently...

Unlock all articles with a

Never miss news about Intellia

Track Intellia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Intellia competitors & trending companies

Browse news for competitors to Intellia and other trending companies.